Sinopharm seals tightly-priced Panda after two-year hiatus
Sinopharm raised Rmb2.8bn ($396m) from a red Panda bond on Saturday. The state-owned traditional Chinese medicine company switched to a shorter tenor to achieve tight pricing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: